Genome-based cancer therapeutics: Targets, kinase drug resistance and future strategies for precision oncology

Current Opinion in Pharmacology

Volumn 13, Issue 4, 2013, Pages 486-496

  Workman, Paul ^a   Al Lazikani, Bissan ^a   Clarke, Paul A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; B RAF KINASE; CRIZOTINIB; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; HEAT SHOCK PROTEIN 90; IMATINIB; ONCOPROTEIN; TRAMETINIB; VEMURAFENIB;

BREAST CANCER; CANCER RESISTANCE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLONAL EVOLUTION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GENOMICS; HUMAN; LUNG NON SMALL CELL CANCER; MACHINE LEARNING; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; ONCOGENE; ONCOGENE SRC; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SOLID TUMOR; SURVIVAL PREDICTION; TUMOR GENE;

EID: 84885957225     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.06.004     Document Type: Review

References (73)

1. Varmus H, Kumar HS: Addressing the growing international challenge of cancer: a multinational perspective. Sci Transl Med 2013, 5 175cm172.
2. Varmus H: The new era in cancer research. Science 2006, 312:1162-1165. (Pubitemid 43801131)
3. Mukherjee S: Emperor of All Maladies. Scribner Book Company; 2011.
4. Yap TA, Workman P: Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol 2012, 52:549-573.
5. Garraway LA, Janne PA: Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012, 2:214-226.
6. Al-Lazikani B, Banerji U, Workman P: Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012, 30:679-692.
7. Vogelstein B, Papadopoulos N, Velculescu VE et al.: Cancer genome landscapes. Science 2013, 339:1546-1558.
8. Garraway LA, Lander ES: Lessons from the cancer genome. Cell 2013, 153:17-37.
9. Forbes SA, Bindal N, Bamford S et al.: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011, 39:D945-D950.
10. Futreal PA, Coin L, Marshall M et al.: A census of human cancer genes. Nat Rev Cancer 2004, 4:177-183. (Pubitemid 38337497)
11. Luo J, Solimini NL, Elledge SJ: Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
12. Iorio MV, Croce CM: MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012, 4:143-159.
13. Dvinge H, Git A, Graf S et al.: The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 2013, 497:378-382.
14. Bilal E, Dutkowski J, Guinney J et al.: Improving breast cancer survival analysis through competition-based multidimensional modeling. PLoS Comput Biol 2013, 9:e1003047.
15. Weinstein IB, Joe A: Oncogene addiction. Cancer Res 2008, 68:3077-3080 discussion 3080.
16. Brough R, Frankum JR, Costa-Cabral S et al.: Searching for synthetic lethality in cancer. Curr Opin Genet Dev 2011, 21: 34-41.
17. Brough R, Frankum JR, Sims D et al.: Functional viability profiles of breast cancer. Cancer Discov 2011, 1:260-273.
18. Patel MN, Halling-Brown MD, Tym JE et al.: Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 2013, 12:35-50.
19. Halling-Brown MD, Bulusu KC, Patel M et al.: canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Res 2012, 40:D947-D956.
20. Zhang J, Yang PL, Gray NS: Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009, 9:28-39.
21. Gaulton A, Bellis LJ, Bento AP et al.: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 2012, 40:D1100-D1107.
22. Gonzalez de Castro D, Clarke PA, Al-Lazikani B, Workman P: Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther 2013, 93:252-259.
23. Knapp S, Arruda P, Blagg J et al.: A public-private partnership to unlock the untargeted kinome. Nat Chem Biol 2013, 9:3-6.
24. Edwards AM, Isserlin R, Bader GD et al.: Too many roads not taken. Nature 2011, 470:163-165.
25. Paez JG, Janne PA, Lee JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. (Pubitemid 38720929)
26. Zhou PC: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall- cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12.
27. Chapman PB, Hauschild A, Robert C et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
28. Shaw AT, Yeap BY, Solomon BJ et al.: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011, 12:1004-1012.
29. Gorre ME, Mohammed M, Ellwood K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880. (Pubitemid 32743979)
30. de Bono JS, Logothetis CJ, Molina A et al.: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
31. Postel-Vinay S, Ashworth A: AXL and acquired resistance to EGFR inhibitors. Nat Genet 2012, 44:835-836.
32. Bivona TG, Hieronymus H, Parker J et al.: FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011, 471:523-526.
33. Sequist LV, Waltman BA, Dias-Santagata D et al.: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
34. Rekhtman N, Paik PK, Arcila ME et al.: Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012, 18:1167-1176.
35. Miller VA, Hirsh V, Cadranel J et al.: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13:528-538.
36. Nurwidya F, Takahashi F, Murakami A, Takahashi K: Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat 2012, 44:151-156.
37. Huang S, Holzel M, Knijnenburg T et al.: MED12 controls the response to multiple cancer drugs through regulation of TGFbeta receptor signaling. Cell 2012, 151:937-950.
38. Girotti MR, Marais R: Deja Vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov 2013, 3:487-490.
39. Davies H, Bignell GR, Cox C et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. (Pubitemid 34716871)
40. Prahallad A, Sun C, Huang S et al.: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
41. Montero-Conde C, Ruiz-Llorente S, Dominguez JM et al.: Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 2013, 3:520-533.
42. Flaherty KT, Infante JR, Daud A et al.: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703.
43. Das Thakur M, Salangsang F, Landman AS et al.: Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013, 494:251-255.
44. Greaves M, Maley CC: Clonal evolution in cancer. Nature 2012, 481:306-313.
45. Duncan JS, Whittle MC, Nakamura K et al.: Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149:307-321.
46. Duy C, Hurtz C, Shojaee S et al.: BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 2011, 473:384-388.
47. She QB, Halilovic E, Ye Q et al.: 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010, 18:39-51.
48. Hoeflich KP, Merchant M, Orr C et al.: Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 2012, 72:210-219.
49. Carver BS, Chapinski C, Wongvipat J et al.: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011, 19:575-586.
50. Kumar MS, Hancock DC, Molina-Arcas M et al.: The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 2012, 149:642-655.
51. Neckers L, Workman P: Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012, 18:64-76.
52. Sang J, Acquaviva J, Friedland JC et al.: Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 2013, 3:430-443.
53. Garnett MJ, Edelman EJ, Heidorn SJ et al.: Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
54. Barretina J, Caponigro G, Stransky N et al.: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
55. Held MA, Langdon CG, Platt JT et al.: Genotype-selective combination therapies for melanoma identified by highthroughput drug screening. Cancer Discov 2013, 3:52-67.
56. Nowell PC: The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
57. Anderson K, Lutz C, van Delft FW et al.: Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-361.
58. Gerlinger M, Rowan AJ, Horswell S et al.: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
59. Cole PA: Chemical probes for histone-modifying enzymes. Nat Chem Biol 2008, 4:590-597.
60. Filippakopoulos P, Qi J, Picaud S et al.: Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
61. Zhang B, Strauss AC, Chu S et al.: Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010, 17:427-442.
62. Sharma SV, Lee DY, Li B et al.: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
63. Fong PC, Yap TA, Boss DS et al.: Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010, 28:2512-2519.
64. Sandhu SK, Omlin A, Hylands L et al.: Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol 2013, 24:1416-1418.
65. Schwartzentruber J, Korshunov A, Liu XY et al.: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482:226-231.
66. Lewis PW, Muller MM, Koletsky MS et al.: Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013, 340:857-861.
67. Bjerke L, Mackay A, Nandhabalan M et al.: Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov 2013.
68. Hodi FS, O'Day SJ, McDermott DF et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
69. Iyer G, Hanrahan AJ, Milowsky MI et al.: Genome sequencing identifies a basis for everolimus sensitivity. Science 2012, 338:221.
70. Kaiser J: Biomedicine. Rare cancer successes spawn 'exceptional' research efforts. Science 2013, 340:263.
71. Janeta Popovici-Muller JOS, Salituro FG, Travins JM, Yan S, Zhao F, Gross S, Dang L, Yen KE, Yang H, Straley KS et al.: Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med Chem Lett 2012, 3:850-855.
72. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
73. Chmielecki J, Foo J, Oxnard GR et al.: Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011, 3:90ra59.